The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Treatment-related symptom management in patients with multiple myeloma: a review
Abstract
Purpose Recent therapeutic advancements have significantly improved overall survival of patients with multiple myeloma (MM). As a result, the impact of disease- and treatment-related symptoms must be managed effectively to improve patient quality of life, given prolonged survival after diagnosis. This review discusses current MM treatment options, effective symptom management approaches, and practical strategies for supportive care. Methods A literature search was performed using MEDLINE/PubMed and scientific congress databases, focusing on clinical trials, review articles, clinical practice guidelines, and other guidance documents on treatment paradigms and supportive care strategies in MM. Additionally, clinical practice worksheets were developed from published sources, and nursing "pearls of wisdom" were gathered from practical experience in the clinic. Results Current therapeutic regimens for relapsed/refractory MM include proteasome inhibitors (i.e., bortezomib, carfilzomib) and immunomodulatory agents (i.e., thalidomide, lenalidomide, pomalidomide), alone or in combination with chemotherapy or corticosteroids. Toxicities associated with agents and combination regimens used in the treatment of MM include myelosuppression, venous thromboembolism, peripheral neuropathy, infections, fatigue, gastrointestinal disorders, and/or cardiac events. Treatment-specific tools and clinical assessments can be useful for optimizing dosing and schedule adjustments to increase therapy duration, and implementing supportive care strategies (e.g., growth factors, transfusional support, intravenous hydration, bisphosphonates, antiviral therapies) to manage treatment-related symptoms. Conclusions Improved survival after MM diagnosis has led to increased patient susceptibility to other diseases and comorbidities due to advanced age. In addition to appropriate drug dosing and administration, effective supportive care and health maintenance are crucial for maximizing quality of life and disease control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Non-targeted drugs, while effective, can also harm normal healthy cells, leading to adverse effects such as gastrointestinal problems (nausea, vomiting, diarrhea, and constipation) [57], myelosuppression (reduction in white blood cells and platelets), alopecia, anemia, liver and kidney impairment, and an increased risk of infections [58, 59].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [58]
Citations
Cites
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Rajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2405062 · Cited by 840
San-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., Trudel, S., Kukreti, V., Bahlis, N., Alsina, M., et al. (2012) · Blood · doi:10.1182/blood-2012-05-425934 · Cited by 657
Proteasome inhibitors in multiple myeloma: 10 years later
Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., & Harousseau, J.-L. (2012) · Blood · doi:10.1182/blood-2012-04-403733 · Cited by 490
Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 432
Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., Rosiñol, L., Boccadoro, M., Cavo, M., Lokhorst, H., et al. (2011) · Blood · doi:10.1182/blood-2011-06-358812 · Cited by 352
Systemic corticosteroid therapy---side effects and their management
STANBURY, R. M., & GRAHAM, E. M. (1998) · British Journal of Ophthalmology · doi:10.1136/bjo.82.6.704 · Cited by 348
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-297325 · Cited by 314
Thalidomide for treatment of multiple myeloma: 10 years later
Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., Moreau, P., Waage, A., Spencer, A., Ludwig, H., et al. (2008) · Blood · doi:10.1182/blood-2007-10-117457 · Cited by 313
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
Lonial, S., Vij, R., Harousseau, J.-L., Facon, T., Moreau, P., Mazumder, A., Kaufman, J. L., Leleu, X., Tsao, L. C., Westland, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2649 · Cited by 296
Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M., Paley, C. S., et al. (2013) · Blood · doi:10.1182/blood-2013-01-481325 · Cited by 290
Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3087 · Cited by 274
Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0433 · Cited by 265
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S. V., et al. (2012) · Leukemia · doi:10.1038/leu.2011.346 · Cited by 253
Dimopoulos, M., Siegel, D. S., Lonial, S., Qi, J., Hajek, R., Facon, T., Rosinol, L., Williams, C., Blacklock, H., Goldschmidt, H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70398-x · Cited by 232
Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0061 · Cited by 226
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
Delforge, M., Bladé, J., Dimopoulos, M. A., Facon, T., Kropff, M., Ludwig, H., Palumbo, A., Van Damme, P., San-Miguel, J. F., & Sonneveld, P. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70068-1 · Cited by 222
van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W. H. I., Lokhorst, H. M., & Mutis, T. (2011) · Haematologica · doi:10.3324/haematol.2010.030759 · Cited by 218
Guidelines for supportive care in multiple myeloma 2011
Snowden, J. A., Ahmedzai, S. H., Ashcroft, J., D’Sa, S., Littlewood, T., Low, E., Lucraft, H., Maclean, R., Feyler, S., Pratt, G., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08574.x · Cited by 206
Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., Testoni, N., Tonelli, M., Vivo, A. D., Palareti, G., et al. (2004) · PubMed · Cited by 191
Unexpected cardiotoxicity in haematological bortezomib treated patients
Orciuolo, E., Buda, G., Cecconi, N., Galimberti, S., Versari, D., Cervetti, G., Salvetti, A., & Petrini, M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06659.x · Cited by 185
Treatment of Multiple Myeloma: A Comprehensive Review
Kyle, R. A., & Rajkumar, S. V. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.n.056 · Cited by 169
Palumbo, A. P., Sezer, O., Kyle, R. A., Miguel, J. F. S., Orlowski, R. Z., Moreau, P., Niesvizky, R., Morgan, G. J., Comenzo, R. L., Sonneveld, P., et al. (2009) · Leukemia · doi:10.1038/leu.2009.122 · Cited by 166
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
Chanan-Khan, A. A., Swaika, A., Paulus, A., Kumar, S. K., Mikhael, J. R., Rajkumar, S. V., Dispenzieri, A. A., & Lacy, M. Q. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.38 · Cited by 158
Miguel, J. F. S., Richardson, P. G. G., Günther, A., Sezer, O., Siegel, D. S. D., Bladé, J., LeBlanc, R., Sutherland, H. J., Sopala, M., Mishra, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.7068 · Cited by 148
Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J. J., & Hussein, M. A. (2006) · Blood · doi:10.1182/blood-2006-01-0154 · Cited by 146
Treatment Options for Relapsed and Refractory Multiple Myeloma
Lonial, S., Mitsiades, C. S., & Richardson, P. G. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1805 · Cited by 139
Petrucci, M. T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M. A., Blau, I. W., Drach, J. W., Angermund, R., Allietta, N., Broer, E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12198 · Cited by 128
Mols, F., Oerlemans, S., Vos, A. H., Koster, A., Verelst, S. G. R., Sonneveld, P., & van de Poll-Franse, L. V. (2012) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2012.01831.x · Cited by 123
Multiple Myeloma: Charging Toward a Bright Future
Katzel, J. A., Hari, P., & Vesole, D. H. (2007) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.57.5.301 · Cited by 121
Moreau, P., Coiteux, V., Hulin, C., Leleu, X. P., de Velde, H. J. V., Acharya, M. R., & Harousseau, J. (2008) · Haematologica · doi:10.3324/haematol.13285 · Cited by 121
Fatigue, Sleep, Pain, Mood, and Performance Status in Patients With Multiple Myeloma
Coleman, E. A., Goodwin, J. A., Coon, S. K., Richards, K. C., Enderlin, C. A., Kennedy, R., Stewart, C. B., McNatt, P., Lockhart, K., Anaissie, E. J., et al. (2010) · Cancer Nursing · doi:10.1097/ncc.0b013e3181f9904d · Cited by 81
Thalidomide and its analogues in the treatment of Multiple Myeloma
Latif, T., Chauhan, N., Khan, R. Z., Moran, A. E., & Usmani, S. Z. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-27 · Cited by 70
Plesner, T., Lokhorst, H. M., Gimsing, P., Nahi, H., Lisby, S., & Richardson, P. G. G. (2012) · Blood · doi:10.1182/blood.v120.21.73.73 · Cited by 70
Febrile neutropenia in haematological malignancies.
Sharma, A., & Lokeshwar, N. (2005) · PubMed · Cited by 68
Yang, B. Y., Yu, R., Chi, X.-H., & Lu, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064354 · Cited by 57
Infections in Patients With Multiple Myeloma
Nucci, M., & Anaissie, E. J. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.03.006 · Cited by 56
Siegel, D. S. D., Richardson, P. G. G., Dimopoulos, M. A., Moreau, P., Mitsiades, C. S., Weber, D., Houp, J., Gause, C. K., Vuocolo, S. C., Eid, J. R., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.1 · Cited by 55
Shortened platelet half-life in multiple myeloma
Fritz, E., Ludwig, H., Scheithauer, W., & Sinzinger, H. (1986) · Blood · doi:10.1182/blood.v68.2.514.514 · Cited by 54
Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R. A., Pliskat, H., Frohn, C., & Hess, G. (2010) · Oncology · doi:10.1159/000322866 · Cited by 48
Richardson, P. G. G., Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., & Anderson, K. C. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0115 · Cited by 48
Reeder, C. B., Reece, D. E., Kukreti, V., Mikhael, J. R., Chen, C. I., Trudel, S., Laumann, K. M., Vohra, H. S., Fonseca, R., Bergsagel, P. L., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13004 · Cited by 45
Dytfeld, D., Jasielec, J. K., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Detweiler‐Short, K., Stockerl-Goldstein, K. E., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.110395 · Cited by 45
Siegel, D. S. D., Dimopoulos, M. A., Yoon, S., Laubach, J. P., Kaufman, J. L., Goldschmidt, H., Reece, D. E., Leleu, X. P., Durrant, S., Offner, F. C., et al. (2011) · Blood · doi:10.1182/blood.v118.21.480.480 · Cited by 45
Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
Schots, R., Fostier, & Becker, A. D. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s28911 · Cited by 40
Smith, L. C., Bertolotti, P., Curran, K., & Jenkins, B. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.s1.37-51 · Cited by 39
Lokhorst, H. M., Plesner, T., Gimsing, P., Nahi, H., Minnema, M. C., Lassen, U., Krejcik, J., Laubach, J. P., Lisby, S., Basse, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8512 · Cited by 36
Singhal, S., Siegel, D. S. D., Martin, T. G., Vij, R., Wang, L., Jakubowiak, A. J., Lonial, S., Kukreti, V., Zonder, J. A., Wong, A., et al. (2011) · Blood · doi:10.1182/blood.v118.21.1876.1876 · Cited by 36
Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives
Jakubowiak, A. J. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.05.003 · Cited by 35
Martin, T. G., Strickland, S. A., Glenn, M. J., Zheng, W., Daskalakis, N., & Mikhael, J. R. (2013) · Blood · doi:10.1182/blood.v122.21.284.284 · Cited by 33
Hanna, L. R., Avila, P. F., Meteer, J. D., Nicholas, D. R., & Kaminsky, L. A. (2008) · Oncology nursing forum · doi:10.1188/08.onf.461-469 · Cited by 32
Problems monitoring response in multiple myeloma
Collins, C. D. (2005) · Cancer Imaging · doi:10.1102/1470-7330.2005.0033 · Cited by 32
Raje, N. S., Vogl, D. T., Hari, P., Jagannath, S., Jones, S. S., Supko, J. G., Leone, G., Wheeler, C., Orlowski, R. Z., Richardson, P. G. G., et al. (2013) · Blood · doi:10.1182/blood.v122.21.759.759 · Cited by 27
Raje, N. S., Hari, P., Vogl, D. T., Jagannath, S., Orlowski, R. Z., Supko, J. G., Stephenson, P. A., Jones, S. S., Wheeler, C., & Lonial, S. (2012) · Blood · doi:10.1182/blood.v120.21.4061.4061 · Cited by 26
Management of disease- and treatment-related complications in patients with multiple myeloma
Gay, F., & Palumbo, A. (2010) · Medical Oncology · doi:10.1007/s12032-010-9542-z · Cited by 25
New Tools for Diagnosis and Monitoring of Multiple Myeloma
Miguel, J. F. S., Paiva, B., & Gutierrez, N. C. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e313 · Cited by 24
Bilotti, E., Faiman, B. M., Richards, T. A., Tariman, J. D., Miceli, T. S., & Rome, S. (2011) · Clinical journal of oncology nursing · doi:10.1188/11.s1.cjon.5-8 · Cited by 23
Rome, S., Doss, D. S., Miller, K. C., & Westphal, J. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.s1.21-27 · Cited by 23
Ocio, E. M., Mateos, M., & Miguel, J. F. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.691164 · Cited by 22
Chen, N., Ye, Y., Liu, L., Reyes, J. F., Assaf, M. S., Kasserra, C., Zhou, S. Y., & Palmisano, M. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12081 · Cited by 21
Wang, M. L., & Cheng, J. (2013) · PubMed · Cited by 21
Forensic expertise at Congress: Melinda Merck talks to John Bonner about her work
Merck, M. D. (2013) · BSAVA Companion · doi:10.22233/20412495.0413.6 · Cited by 21
Bortezomib for AL amyloidosis: moving forward
Dimopoulos, M. A., & Kastritis, E. (2011) · Blood · doi:10.1182/blood-2011-05-355115 · Cited by 21
Richardson, P. G. G., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Guenther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8510 · Cited by 19
Lonial, S., Jagannath, S., Moreau, P., Jakubowiak, A. J., Raab, M. S., Facon, T. T. F., Vij, R., Bleickardt, E. W., Reece, D. E., Benboubker, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8542 · Cited by 19
Niesvizky, R., & Badros, A. Z. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0112 · Cited by 16
Siegel, D. S. D., Richardson, P. G. G., Dimopoulos, M. A., Moreau, P., Mitsiades, C. S., Weber, D. M., Houp, J., Gause, C. K., Vuocolo, S. C., Eid, J. R., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.23 · Cited by 15
Yee, A. J., Vorhees, P., Bensinger, W., Berdeja, J. G., Supko, J. G., Richardson, P. G. G., Jones, S. S., Patrick, G., Wheeler, C., & Raje, N. S. (2013) · Blood · doi:10.1182/blood.v122.21.3190.3190 · Cited by 15
Clinical Updates and Nursing Considerations for Patients With Multiple Myeloma
Faiman, B. M. (2007) · Clinical journal of oncology nursing · doi:10.1188/07.cjon.831-840 · Cited by 14
Bringhen, S., Gay, F., Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.712685 · Cited by 11
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Vij, R. (2011) · PubMed · Cited by 9
Quality of Life Issues of Patients with Multiple Myeloma
Gadó, K., & Domja, G. (2013) · InTech eBooks · doi:10.5772/55625 · Cited by 6
Factor XII Promotes Leukocyte Inflammation and Its Deficiency Results in Faster Wound Healing
Stavrou, E. X., Larusch, G. A., Fullana, M. J., Wnek, G. E., Qu, C., Yu, W., Meyerson, H. J., Fang, C., Ziats, N. P., & Schmaier, A. H. (2011) · Blood · doi:10.1182/blood.v118.21.368.368 · Cited by 6
Blood and neoplastic diseases. Thrombocytopenia.
Barkhan, P. (1974) · BMJ · doi:10.1136/bmj.2.5914.324 · Cited by 6
Research works printed but not linked: 1
- Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute
Cited by
Chemotherapy-induced peripheral neurotoxicity
Cavaletti, G., & Marmiroli, P. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000234 · Cited by 239
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Engelhardt, M. M., Ihorst, G., Singh, M., Rieth, A., Saba, G., Pellan, M., & Lebioda, A. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.10.002 · Cited by 60
Kiely, F., Cran, A., Finnerty, D., & O’Brien, T. (2016) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909116646337 · Cited by 50
The power of proteasome inhibition in multiple myeloma
Guerrero-Garcia, T. A., Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Mitsiades, C. S., Anderson, K. C., & Richardson, P. G. G. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1543595 · Cited by 38
Metadata
- Authors
- Colson, K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Colson, Kathleen
- Venue
- Supportive Care in Cancer
- Published
- 2015-02-03
- Volume
- 23
- Issue
- 5
- Pages
- 1431-1445
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W1981758758
- Cited by
- 51
- References
- 83
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 6 · 2023: 1 · 2022: 5 · 2021: 1 · 2020: 6 · 2019: 1 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 4
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- multiple myeloma, treatment-related symptoms, supportive care, relapsed/refractory multiple myeloma, proteasome inhibitors, immunomodulators, myelosuppression, venous thromboembolism, peripheral neuropathy, fatigue, drug toxicity, growth factors, bisphosphonates, antiviral therapy, quality of life, nursing care
- MeSH terms
- Bortezomib, Lenalidomide, Antineoplastic Agents, Boronic Acids, Humans, Immunologic Factors, Multiple Myeloma, Oligopeptides, Peripheral Nervous System Diseases, Pyrazines, Quality of Life, Thalidomide, Immunomodulation, Proteasome Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.